Drugs / 18F-FAZA

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT00323076 Sep 2006 → Feb 2019 neuroendocrine neoplasm, renal cell carcinoma AHS Cancer Control Alberta Terminated No outcome recorded
Phase 22 trials
Phase 2 NCT02802969 Jul 2016 → Nov 2024 skull base chordoma, spinal chordoma Institut Curie Completed No outcome recorded
Phase 2 NCT00771381 Nov 2008 → Feb 2019 breast neoplasm AHS Cancer Control Alberta Terminated No outcome recorded
Phase not applicable3 trials
NCT04395469 May 2021 → Mar 2027 expected pancreatic adenocarcinoma University Health Network, Toronto Active not recruiting No outcome recorded
NCT03418818 Mar 2018 → Oct 2028 expected sarcoma University Health Network, Toronto Active not recruiting No outcome recorded
NCT02496832 Nov 2014 metastatic neoplasm, pancreatic adenocarcinoma University Health Network, Toronto Withdrawn No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as [18]F-FAZA “A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head & Neck,...” NCT00323076
5

NCT04395469

NCT00771381

NCT03418818

NCT00323076

NCT02802969

Known as 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole “A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head & Neck,...” NCT00323076
Known as 18F-Fluoroazomycin arabinoside ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496832
Modality Diagnostic / imaging agent “The PET tracer [18]F-FAZA can identify hypoxic areas” NCT00323076